This new research, published in the Genes & Diseases journal by a scientific team from Qilu Hospital of Shandong University, investigated the precise role of eEF1A2 and its specific methyltransferase, EEF1AKMT4, in GBC tumor progression and lymphatic spread.

Transcriptome sequencing of paired GBC tumors and metastatic lymph nodes, alongside clinical cohort analyses, revealed that eEF1A2 is significantly overexpressed in GBC and tightly correlates with advanced lymph node metastasis and poor patient survival. Through rigorous in vitro and in vivo experiments, including a specialized mouse popliteal lymph node metastasis model, researchers demonstrated that eEF1A2 significantly promotes GBC cell proliferation, migration, and invasion.

Mass spectrometry and functional analyses identified that EEF1AKMT4 specifically trimethylates eEF1A2 at the K36 site, a location critically positioned near the protein's GDP-binding pocket. This specific K36 trimethylation increases the GTPase catalytic activity of eEF1A2, thereby accelerating overall ribosomal protein synthesis. This elevated translational output consequently upregulates key tumor-promoting signals, most notably the ERK1/2 and AKT pathways.

Further functional experiments validated this mechanism, showing that introducing a K36R mutation to block methylation, or knocking down EEF1AKMT4 entirely, successfully abolished eEF1A2’s oncogenic effects.

Remarkably, in vivo models confirmed that inhibiting the EEF1AKMT4-eEF1A2 signaling axis significantly impaired tumor growth and sharply reduced the volume of metastatic lymph nodes. While these collective data robustly highlight the critical influence of localized protein translation efficiency on GBC aggressiveness, additional studies are necessary to fully realize these targeted interventions in a clinical setting.

In conclusion, targeting the evolutionarily conserved EEF1AKMT4-eEF1A2K36me3 signaling axis offers a powerful strategy to suppress translation-driven tumor growth and halt lymphatic spread. This profound finding positions specific inhibitors of eEF1A2 and its K36 trimethylation as compelling therapeutic candidates for the next generation of gallbladder cancer treatments.

Reference

Title of Original Paper: EEF1AKMT4-eEF1A2 synergistically facilitates the progression of GBC by promoting ribosomal protein output

Journal: Genes & Diseases

Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI: https://doi.org/10.1016/j.gendis.2025.101619

Funding Information:

• The Shandong Province Natural Science Foundation, China (Grant No. ZR2024MH328, No. ZR2021QH079, No. ZR2019MH008, No. ZR2020MH238)
• Shandong Province Key R&D Program (Major Scientific Innovation Projects), China (No. 2021CXGC011105)
• National Natural Science Foundation of China (Grant No. 81900728, No. 82072676, No. 82172791, No. 82203766)
• Shandong Medical and Health Technology Development Project, China (Grant No. 2018WSB20002)
• Clinical Research Foundation of Shandong University, China (Grant No. 2020SDUCRCA018)
• Key Research and Development Program of Shandong Province, China (Grant No. 2019GSF108254)

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus Cite Score: 8.4
Impact Factor: 9.4
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).

Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R

Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)